Skip to content

Clinical observation of acupuncture in treating breast cancer fatigue

Clinical observation of acupuncture in treating breast cancer fatigue

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069361
Enrollment
Unknown
Registered
2023-03-14
Start date
2023-03-15
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-related fatigue

Interventions

Acupuncture group:Acupuncture
Comfort acupuncture group:pseudoacupuncture

Sponsors

The Second Affiliated Hospital of Guizhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria of cancer-induced fatigue; The diagnosis was neoplastic (malignant) associated fatigue (ICD-10-CD diagnostic code R53.0). Eligible patients were diagnosed with stage I, II, or IIIA breast cancer; 2. The age of patients was 18-75 years old; 3. Vital signs were stable, conscious, able to cooperate with examination and treatment, and the concise Fatigue Scale (BFI) score of 4 or above; 4. Completion of chemotherapy at least 1 month and 5 years ago (recruit those with persistent/long-term fatigue); 5. No drug treatment related to this study within 2 weeks before the study, no acupuncture treatment within 1 month before the study, or participating in other clinical studies; 6. Sign informed consent and participate in this study voluntarily.

Exclusion criteria

Exclusion criteria: 1. Do not meet the above diagnostic criteria and inclusion criteria; 2. Any conditions that may prevent subjects from completing the clinical trial process, including but not limited to severe, uncontrollable organic disease or infection, unstable angina, congestive heart failure, etc.; 3. Patients with symptoms, uncontrollable neurological, mental diseases or mental disorders; 4. Patients with poor compliance; 5. In pregnancy or lactation period, nearly 8 months have a pregnancy plan patients; 6. Combined with bleeding disease or thyroid dysfunction, concurrent surgery, immunotherapy or radiotherapy; 7. Patients who may be affected by the use of the drug during treatment and who may take the drug related to this study (if starting hormone therapy within the past 3 weeks; And a change in the use of serotonin reuptake inhibitors (SSRIs) within the past 6 weeks, or opioid or non-SSRI antidepressants within the past 3 weeks); 8. Have had acupuncture treatment in nearly 3 months; 9. Severe fear of needles, fainting needles or metal allergy; 10. Life expectancy is less than six months.

Design outcomes

Primary

MeasureTime frame
Multidimensional fatigue symptom MFI-20 scale score;

Secondary

MeasureTime frame
Brief Fatigue Inventory, BFI scale;

Countries

China

Contacts

Public ContactMo Qian

The Second Affiliated Hospital of Guizhou University of Chinese Medicine

Duoduo425@126.com+86 182 8618 0926

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026